Hyperprolactinemia
disease diseaseOn this page
Also known as hyperprolactinaemiahyperprolactinemia (disease)hyperprolactinemiashypersecretion syndrome, prolactininappropriate prolactin secretioninappropriate prolactin secretion syndromeinappropriate secretion prolactinprolactin hypersecretion syndromeprolactin secretion, inappropriateprolactin, inappropriate secretionsecretion prolactin, inappropriatesecretion, inappropriate prolactinsyndrome, prolactin hypersecretion
Summary
Hyperprolactinemia (MONDO:0005804) is a disease and 27 clinical trials. Top therapeutic interventions include aripiprazole, ropinirole, and bromocriptine. A subtype of hyperpituitarism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 27
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hyperprolactinemia |
| Mondo ID | MONDO:0005804 |
| EFO | EFO:0007319 |
| MeSH | D006966 |
| ICD-10-CM | E22.1 |
| SNOMED CT | 237662005 |
| UMLS | C0020514 |
| MedGen | 5698 |
| Is cancer (heuristic) | no |
Also known as: hyperprolactinaemia · hyperprolactinemia · hyperprolactinemia (disease) · hyperprolactinemias · hypersecretion syndrome, prolactin · inappropriate prolactin secretion · inappropriate prolactin secretion syndrome · inappropriate secretion prolactin · prolactin hypersecretion syndrome · prolactin secretion, inappropriate · prolactin, inappropriate secretion · secretion prolactin, inappropriate · secretion, inappropriate prolactin · syndrome, prolactin hypersecretion
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of hyperpituitarism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › pituitary gland disorder › anterior pituitary gland disorder › hyperpituitarism › hyperprolactinemia
Related subtypes (3): acromegaly, pituitary gigantism, ACTH-dependent Cushing syndrome
Subtypes (2): familial hyperprolactinemia, acquired hyperprolactinemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Calcium | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE4 | 5 |
| PHASE2 | 3 |
| PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00541554 | PHASE4 | UNKNOWN | Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia |
| NCT00625950 | PHASE4 | COMPLETED | Endometriosis Patients Undergoing Quinagolide Treatment |
| NCT00889512 | PHASE4 | TERMINATED | The Luveris In Vitro Fertilization Trial |
| NCT01085383 | PHASE4 | COMPLETED | Aripiprazole and Prolactin Study |
| NCT01742390 | PHASE4 | UNKNOWN | A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders |
| NCT07124221 | PHASE3 | RECRUITING | A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets |
| NCT00315081 | PHASE3 | UNKNOWN | Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine |
| NCT01852331 | PHASE2 | COMPLETED | Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia |
| NCT02956447 | PHASE2 | COMPLETED | Administration of Kisspeptin in Patients With Hyperprolactinemia |
| NCT03038308 | PHASE1/PHASE2 | COMPLETED | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole |
| NCT03709849 | PHASE2 | UNKNOWN | Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility |
| NCT07008417 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study on Bioequivalence of Cabergoline Tablets in Human Body |
| NCT00914823 | PHASE1 | COMPLETED | Kisspeptin Administration in the Adult |
| NCT06870773 | Not specified | NOT_YET_RECRUITING | Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women to Determine Whether H. Pylori Infection is Associated with Elevated Prolactin Levels and Assess the Clinical Implications |
| NCT00436111 | Not specified | COMPLETED | Characterization of Macroprolactinemia |
| NCT00699530 | Not specified | WITHDRAWN | Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment |
| NCT01052948 | Not specified | COMPLETED | The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events |
| NCT01270711 | Not specified | COMPLETED | Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) |
| NCT01338298 | Not specified | COMPLETED | Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia |
| NCT02098668 | Not specified | COMPLETED | Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON |
| NCT02603549 | Not specified | SUSPENDED | Pituitary Function and Spontaneous Intracranial Hypotension |
| NCT03569787 | Not specified | COMPLETED | Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire |
| NCT04146389 | Not specified | TERMINATED | Hyperprolactinemia and Adrenal Steroidogenesis |
| NCT04439747 | Not specified | UNKNOWN | Develop and Implement Methods for Diagnostic and Treatment of Hormonal Disorders in Patients With Chronic Kidney Disease |
| NCT04746313 | Not specified | COMPLETED | Prevalence of Hyperprolactinemia in Systemic Scleroderma |
| NCT05033119 | Not specified | COMPLETED | PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics |
| NCT06326840 | Not specified | COMPLETED | Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ARIPIPRAZOLE | 4 | 4 |
| ROPINIROLE | 4 | 3 |
| BROMOCRIPTINE | 4 | 2 |
| CABERGOLINE | 4 | 2 |
| GONADORELIN ACETATE | 4 | 2 |
| KISSPEPTIN | 2 | 2 |
| CHEMBL4593105 | 0 | 2 |
| CHEMBL5192470 | 0 | 2 |
| CHEMBL2370644 | 0 | 2 |